Value Genome LLC

We are Value Genome, a global value actualization firm specializing in oncology and rare disease that assists biotechnology companies in developing strategy and evidence-based messaging, driven by research with clinical thought leaders, payers and health technology assessment organizations, to maximize the commercial value of innovative medicines. By leveraging our deep expertise in Gene Therapy Market Access, Medical Affairs, Health Economics and Outcomes Research (HEOR) and Patient Advocacy, we empower you to strengthen your product's value proposition and achieve optimal financial returns—whether through licensing, acquisition or market entry. We believe that proactively integrating clinical efficacy and economic value early is crucial for securing reimbursement and maximizing market potential. Many companies delay these steps, which may impact negotiating power and profitability. Our tailored approach reveals the value of your assets through the lens of key stakeholders, ensuring that your efforts translate into maximum financial returns. Value Genome is a collaboration of former pharmaceutical and biotechnology executives, united by a common passion for helping innovators actualize the clinical and economic value of their assets. By combining our scientific, clinical, economic and commercialization expertise with extensive payer and KOL research and relations experience, we ensure that therapies meet the highest standards of safety and efficacy while remaining accessible to those who need them most. Contact Value Genome to arrange a strategic consultation on how our differentiated approach will capture, quantify, and communicate the full value of your assets.